Références

[1] Reardon MJ, van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2017;376:1321–31 10.1056/NEJMoa1700456 [28304219]

[2] Laptook AR, Shankaran S, Tyson JE, et al. Effect of Therapeutic Hypothermia Initiated After 6 Hours of Age on Death or Disability Among Newborns With Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial. JAMA 2017;318:1550–60 10.1001/jama.2017.14972 [29067428]

[3] Kapur J, Elm J, Chamberlain JM, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med 2019;381:2103–13 10.1056/NEJMoa1905795 [31774955]

[4] Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 2021;9:295–304 10.1016/S2213-2600(20)30556-7 [33493450]

[5] Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021 10.1056/NEJMoa2105911 [34351721]

[6] Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 2021;397:1063–74 10.1016/S0140-6736(21)00461-X [33676597]

[7] Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. Ann Am Thorac Soc 2020;17:879–91 10.1513/AnnalsATS.202003-192SD [32267771]

[8] Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020;324:1317–29 10.1001/jama.2020.17022 [32876697]

[9] Arabi YM, Gordon AC, Derde LPG, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med 2021;47:867–86 10.1007/s00134-021-06448-5 [34251506]

[10] Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 2021;384:1491–502 10.1056/NEJMoa2100433 [33631065]

[11] Hermine O, Mariette X, Tharaux P-L, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med 2021;181:32–40 10.1001/jamainternmed.2020.6820 [33080017]

[12] Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. N Engl J Med 2021 10.1056/NEJMoa2103784 [34407339]

[13] Houston BL, Lawler PR, Goligher EC, et al. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clin Trials 2020:1740774520943846 10.1177/1740774520943846 [32815416]

[14] Ioannidis JPA. Why most published research findings are false. PLOS Medicine 2005;2:e124 10.1371/journal.pmed.0020124 [16060722]

[15] Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? BMJ 2001;322:226–31 10.1136/bmj.322.7280.226 [11159626]

[16] Cucherat M, Laporte S. Les résultats faux positifs ou quelle est la probabilité que le traitement soit efficace quand p < 0,05 ? Thérapie 2017;72:421–26 10.1016/j.therap.2016.09.021 [28577824]

[17] Kaul S. Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True? Circulation 2016;134:94–96 10.1161/CIRCULATIONAHA.116.022537 [27400894]

[18] Pibouleau L, Chevret S. Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices. Journal of Clinical Epidemiology 2011;64:270–79 10.1016/j.jclinepi.2010.03.018 [20800443]

[19] Sobieraj DM, Cappelleri JC, Baker WL, et al. Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review. BMJ open 2013;3 10.1136/bmjopen-2013-003111

[20] Kruschke JK. Bayesian Analysis Reporting Guidelines. Nat Hum Behav 2021;5:1282–91 10.1038/s41562-021-01177-7 [34400814]

[21] Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 2020;383:546–57 10.1056/NEJMoa1917246 [32757523]

[22] INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE. ADDENDUM ON ESTIMANDS AND SENSITIVITY ANALYSIS IN CLINICAL TRIALS TO THE GUIDELINE ON STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E9(R1).

[23] LeLorier J, Grégoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. New Engl J Med 1997;337:536–42 10.1056/NEJM199708213370806 [9262498]

[24] Bailar JC. The promise and problems of meta-analysis. New Engl J Med 1997;337:559–61 10.1056/NEJM199708213370810 [9262502]

[25] Ibrahim JG, Chen M-H, Sinha D. On Optimality Properties of the Power Prior. Journal of the American Statistical Association 2003;98:204–13 10.1198/016214503388619229

[26] Nissen SB, Magidson T, Gross K, et al. Publication bias and the canonization of false facts. eLife 2016;5 10.7554/eLife.21451 [27995896]

[27] Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:1833–42 10.1016/S0140-6736(17)32247-X [28855077]

[28] Absolutely Maybe. Reproducibility Crisis Timeline: Milestones in Tackling Research Reliability - Absolutely Maybe 2016 Accessed March 24, 2022.

[29] Tajika A, Ogawa Y, Takeshima N, et al. Replication and contradiction of highly cited research papers in psychiatry: 10-year follow-up. Br J Psychiatry 2015;207:357–62 10.1192/bjp.bp.113.143701 [26159600]

[30] Tatsioni A, Bonitsis NG, Ioannidis JPA. Persistence of contradicted claims in the literature. JAMA 2007;298:2517–26 10.1001/jama.298.21.2517 [18056905]

[31] Hwang TJ, Carpenter D, Lauffenburger JC, et al. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Intern Med 2016;176:1826–33 10.1001/jamainternmed.2016.6008 [27723879]

[32] Nagendran M, Pereira TV, Kiew G, et al. Very large treatment effects in randomised trials as an empirical marker to indicate whether subsequent trials are necessary: meta-epidemiological assessment. BMJ 2016;355:i5432 10.1136/bmj.i5432 [27789483]

[33] Kaul S. Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True? Circulation 2016;134:94–96 10.1161/CIRCULATIONAHA.116.022537 [27400894]